Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Small Cell Lung Carcinoma 4Triple Negative Breast Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Pathologic Complete Response 1Neutropenia 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Limited Stage Small Cell Lung Cancer 1Hemangiosarcoma 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 105Specimen Handling 55Magnetic Resonance Spectroscopy 48Biopsy 47Nivolumab 39Paclitaxel 35Radiosurgery 30Gemcitabine 30Carboplatin 30Cisplatin 23Irinotecan 22Ipilimumab 22Cyclophosphamide 22trastuzumab deruxtecan 21Leucovorin 19Capecitabine 19Fluorouracil 18Cetuximab 18Bevacizumab 18130-nm albumin-bound paclitaxel 18Pemetrexed 17Fulvestrant 17Drug Therapy 16Docetaxel 16Taxes 15Oxaliplatin 15olaparib 14abemaciclib 14Radiotherapy 14atezolizumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × trilaciclib × 1 year × Clear all
NCT06027268 2026-04-22

ToPCourT

Wake Forest University Health Sciences

Phase 2 Active not recruiting
36 enrolled
Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡